Blood Cancer Journal最新文献

{"title":"Selinexor for myelofibrosis or a drug in search of a disease?","authors":"Naseema Gangat, Ayalew Tefferi","doi":"10.1038/s41408-026-01587-8","DOIUrl":"10.1038/s41408-026-01587-8","url":null,"abstract":"<p><p>Selinexor for the Treatment of Myelofibrosis. SVR35- spleen volume reduction ≥ 35%, TSS- total symptom score.</p>","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"16 1","pages":""},"PeriodicalIF":13.8,"publicationDate":"2026-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13401593/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148590412","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Linvoseltamab outcomes by frailty status in patients with relapsed/refractory multiple myeloma: a subgroup analysis of the LINKER-MM1 study","authors":"Hira Mian, Naresh Bumma, Joshua Richter, Mina Awad, Timothy J. Inocencio, C. Akunna Otele, Megan Seraphin, Tito Roccia, Glenn S. Kroog, Tanya M. Wildes","doi":"10.1038/s41408-026-01572-1","DOIUrl":"https://doi.org/10.1038/s41408-026-01572-1","url":null,"abstract":"There is a paucity of data in frail patients with multiple myeloma (MM) receiving bispecific antibodies (bsAbs). In LINKER-MM1 (NCT03761108), linvoseltamab (human BCMA×CD3 bsAb) demonstrated high response rates and a generally manageable safety profile in relapsed/refractory (RR)MM. This LINKER-MM1 post hoc analysis evaluated outcomes of linvoseltamab 200 mg in patients categorized for frailty using the International Myeloma Working Group Frailty Proxy (IMWG-FP), Simplified Frailty Score (SFS), and patient-reported frailty phenotype (PRFP). As of July 23, 2024, 117 patients received linvoseltamab (median follow-up: 21.3 months). The percentage of frail patients varied by measure: IMWG-FP, 27.4%; SFS, 26.5%; and PRFP, 20.5% (8/4 patients were excluded due to missing IMWG-FP/PRFP scores, respectively). Objective response rates in non-frail and frail groups, respectively, were: IMWG-FP, 72.7% and 65.6%; SFS, 69.8% and 74.2%; PRFP, 73.0% and 62.5%. Incidence of Grade 3/4 treatment-emergent adverse events was consistent across non-frail and frail groups (IMWG-FP: 72.7% and 75.0%; SFS%: 73.3% and 74.2; PRFP: 74.2% and 70.8, respectively). Clinical outcomes were consistent in non-frail and frail groups, indicating a favorable risk–benefit profile for linvoseltamab in the frail patients with RRMM from LINKER-MM1. Continued evaluation of linvoseltamab in frail patients with RRMM in clinical trials and real-world settings is warranted.","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"13 1","pages":""},"PeriodicalIF":12.8,"publicationDate":"2026-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148587267","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A multicentre phase III clinical trial of dual-epigenetic therapy plus CHOP compared with CHOP in previously untreated patients with peripheral T-cell lymphoma","authors":"Chong Wei, Liping Su, Xiaobo Wang, Yang Song, Ningbin Chen, Yuanyan Tang, Aijun Liao, Wei Yang, Zhiming Li, Jing Shen, Daobin Zhou, Wei Zhang","doi":"10.1038/s41408-026-01570-3","DOIUrl":"https://doi.org/10.1038/s41408-026-01570-3","url":null,"abstract":"This phase 3 multicenter trial evaluated the efficacy and safety of adding dual epigenetic agents azacitidine and chidamide to CHOP (AC-CHOP) versus CHOP alone in previously untreated peripheral T-cell lymphoma (PTCL). A total of 128 patients were enrolled from 9 centers in China and assigned according to participating centers (AC-CHOP, N = 84; CHOP, N = 44). Azacitidine 200 mg on days 1–2, 100 mg on day 3 and chidamide 20 mg twice weekly were administered in the AC-CHOP arm. The AC-CHOP arm showed numerically higher ORR (60.7% vs. 54.6%) and CR rate (47.6% vs. 36.4%) than the CHOP arm, although the differences were not statistically significant. A trend toward improved PFS was observed in the AC-CHOP arm (median 10.2 months in the AC-CHOP arm vs. 8.4 months in the CHOP arm, P = 0.093), alongside a significantly improved OS (median 46.2 months vs. 24.1 months, P = 0.023). The safety profile was comparable between the two groups, with hematologic toxicity and infection being the most common adverse events. Genomic profiling showed that DNMT3A mutations were associated with lower response rates, while IDH2 and TP53 mutations were associated with inferior survival outcomes. In conclusion, the addition of chidamide and azacitidine to CHOP did not significantly improve ORR or PFS. Although OS was longer in the AC-CHOP arm, this finding should be interpreted cautiously given the imbalances in post-protocol treatments between the two arms. Integration of molecular profiling may improve risk stratification and inform future biomarker-driven therapeutic strategies in PTCL.","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"13 1","pages":""},"PeriodicalIF":12.8,"publicationDate":"2026-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148587268","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment patterns and outcomes for second-line therapy in large B-cell lymphoma: results from the LEO CReWE study","authors":"Jean L. Koff, Melissa C. Larson, Jonathon B. Cohen, Izidore S. Lossos, Peter Martin, Thomas M. Habermann, Carla Casulo, Samuel Yamshon, Andrea Lo-Rossi, Ashwini Shewade, Connie Lee Batlevi, Anthony Masaquel, Yong Mun, Yucai Wang, Arushi Khurana, Grzegorz S. Nowakowski, Dai Chihara, Eric Mou, Umar Farooq, Dilan Patel, Amy Ayers, Tanner W. Reicks, James R. Cerhan, Christopher R. Flowers, Matthew J. Maurer, Loretta J. Nastoupil","doi":"10.1038/s41408-026-01563-2","DOIUrl":"https://doi.org/10.1038/s41408-026-01563-2","url":null,"abstract":"Treatment strategies for relapsed/refractory large B-cell lymphoma (R/R LBCL) have evolved rapidly, yet relationships between therapy selection and outcomes remain poorly defined. The LEO CReWE study evaluated disease characteristics, patterns of care, and outcomes in 1504 patients with R/R LBCL from 2002 to 2022. Of these, 64% received chemoimmunotherapy at second-line (2L). Autologous stem cell transplant (ASCT) and/or chimeric antigen receptor T-cell therapy (CAR-T) were planned at 2L for 984 patients (65%), with 471 (31%) ultimately receiving ASCT and 94 (6%) receiving CAR-T. Complete response (CR) rates at 2L ranged from 24% for lenalidomide-based regimens to 49% for CAR-T; salvage chemotherapy achieved a 44% CR rate overall and 60% among patients who eventually underwent ASCT. Median event-free and overall survival from 2L were 4.3 months and 18.3 months, respectively; survival improved in eras during which CAR-T was available. Patients intended for but unable to receive ASCT or CAR-T experienced poor outcomes comparable to those never intended for curative therapy at 2L. The LEO CReWE study represents the first large-scale depiction of 2L treatment patterns and outcomes for LBCL in the modern era, inclusive of all treatment approaches, and underscores the ongoing need for more effective therapies despite the advent of CAR-T.","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"47 1","pages":""},"PeriodicalIF":12.8,"publicationDate":"2026-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148587269","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"SECURE study: baseline findings from a UK prospective cohort of incidentally detected MGUS.","authors":"Elizabeth Knight,Anupama Krishnamoorthi,Berrin Balik,Sulgi Byun,Richard Brouwer,Guy Pratt,Ross Sadler,Supratik Basu,Simon Stern,Stella Bowcock,Fenella Willis,Vicki Gamble,Aimee Maloney,Roderick Oakes,Grace Killingsworth,Patricia Nicholls,Karthik Ramasamy","doi":"10.1038/s41408-026-01576-x","DOIUrl":"https://doi.org/10.1038/s41408-026-01576-x","url":null,"abstract":"","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"44 1","pages":""},"PeriodicalIF":12.8,"publicationDate":"2026-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148522122","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Single agent selinexor is active in patients with myelofibrosis refractory or intolerant to JAK inhibitors.","authors":"Srinivas K Tantravahi,Andrea A Ellero,Ami B Patel,Brynn Parsegov,Christopher J Walker,Jeffrey T Yap,Kenneth M Boucher,Anton V Rets,Josef T Prchal,Michael W Deininger","doi":"10.1038/s41408-026-01571-2","DOIUrl":"https://doi.org/10.1038/s41408-026-01571-2","url":null,"abstract":"","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"28 1","pages":""},"PeriodicalIF":12.8,"publicationDate":"2026-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148522262","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The blood remembers: HSC-iM and the cancer continuum.","authors":"Juan L Coelho-Silva,Diego A Pereira-Martins,João A Machado-Neto","doi":"10.1038/s41408-026-01581-0","DOIUrl":"https://doi.org/10.1038/s41408-026-01581-0","url":null,"abstract":"","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"455 1","pages":""},"PeriodicalIF":12.8,"publicationDate":"2026-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148522123","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Newly diagnosed acute myeloid leukemia in Fit patients: 2026 treatment algorithms.","authors":"Naseema Gangat, Farhad Ravandi","doi":"10.1038/s41408-026-01578-9","DOIUrl":"https://doi.org/10.1038/s41408-026-01578-9","url":null,"abstract":"<p><p>The introduction of venetoclax (a BCL2 inhibitor) and targeted therapies, including inhibitors of CD33, FLT3, IDH1, IDH2, and menin, has expanded treatment options for newly diagnosed acute myeloid leukemia (AML). In younger, fit patients, the primary goal remains long-term survival, which in most cases is secured through allogeneic stem cell transplant. Transplant in first complete remission is recommended for FLT-ITD, TP53 mutated, KMT2A rearranged, AML with other adverse genetic abnormalities, and is considered in most intermediate-risk patients. It is also recommended in relapsed/refractory disease or persistent measurable residual disease (MRD). The role of intensive chemotherapy, such as cytarabine (7) plus anthracycline (3), is limited to patients with core-binding factor AML, NPM1 mutation, CEBPA bZIP mutation and those with intermediate-risk disease. Intensive regimens such as FLAG-IDA and CLIA plus venetoclax have shown impressive long-term outcomes, but their use is not widespread. In FLT3 mutated AML, 7 + 3 plus an FLT3 inhibitor (midostaurin or quizartinib) remains a standard, with venetoclax-hypomethylating agent-FLT3 inhibitor triplets emerging as an alternative. Similarly, in IDH1/2 mutated AML, venetoclax-hypomethylating agent with or without IDH1/2 inhibitor combinations challenge intensive chemotherapy approaches. Patients with TP53 mutations or other adverse-risk features, where intensive chemotherapy is known to be less effective, should be referred for clinical trials. There remains ongoing debate regarding optimal management of fit patients with newly diagnosed AML without targetable mutations, as emerging data suggest that venetoclax- hypomethylating agents may be comparable to intensive chemotherapy in selected patients proceeding to transplant. Accordingly, treatment decisions should be individualized to maximize remission while minimizing toxicity.</p>","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":" ","pages":""},"PeriodicalIF":13.8,"publicationDate":"2026-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148497060","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Combination of daratumumab, ixazomib, and lenalidomide with or without dexamethasone for initial therapy of newly diagnosed myeloma","authors":"Shaji Kumar, Betsy Knopf, Erik Asmus, Eli Muchtar, Francis K. Buadi, Wilson Gonsalves, Melanie Thompson, David Dingli, Ronald Go, Rahma Warsame, Taxiarchis Kourelis, Lisa Hwa, Amie Fonder, Miriam Hobbs, Angela Dispenzieri, Suzanne Hayman, Nelson Leung, Moritz Binder, S. Vincent Rajkumar, Morie Gertz, Prashant Kapoor","doi":"10.1038/s41408-026-01567-y","DOIUrl":"https://doi.org/10.1038/s41408-026-01567-y","url":null,"abstract":"Quadruplets incorporating anti-CD38 monoclonal antibody have led to improved outcomes, potentially allowing limited-duration therapy and reduction in steroid doses. We designed this trial to examine the efficacy of the quadruplet regimen containing daratumumab, ixazomib, lenalidomide, and dexamethasone (Dara-IRd) given for fixed duration and to evaluate early discontinuation of steroids. Patients with untreated MM were enrolled, irrespective of their transplant eligibility. The primary objective was to determine the ≥complete response (CR) rate. Treatment involved 28-day cycles of ixazomib 4 mg days 1, 8, 15; lenalidomide 25 mg days 1–21, dexamethasone 40 mg, weekly and daratumumab 16 mg/kg, weekly for two cycles, every other week during cycles 3–6 and every 4-weeks thereafter during induction (12-cycles) followed by daratumumab and ixazomib maintenance (24-cycles). Seventy-eight patients were enrolled into two sequential cohorts: cohort A ( <jats:italic>n</jats:italic> = 38) and B ( <jats:italic>N</jats:italic> = 40), with dexamethasone given only for two cycles in Cohort B. At the time of the data cut-off, all patients had completed the treatment. The overall response rate was 96%, including a ≥CR rate of 32%, similar in both cohorts. Responses deepened over time; 32% achieved a marrow MRD negative status and 29% MRD <jats:sub>neg</jats:sub> -CR. After a median follow-up of 37.9 months, the median PFS or OS has not been reached. A grade ≥3 adverse event, at least possibly attributed to the study drugs, was seen in 55% of patients. The most common toxicities included fatigue, neutropenia, lymphopenia, peripheral neuropathy, diarrhea, and nausea. Stem cells were collected in 55 patients; the median sCD34+ cell yield (range) was 7.8 (2.8–15.9) × 10 <jats:sup>6</jats:sup> /kg. Dara-IRd is an active regimen in newly diagnosed MM, with high overall response rate as well as deep responses. Nearly a third of the patients attained MRD <jats:sub>neg</jats:sub> status, which improved over time. The PFS with finite-duration therapy is comparable to other studies in NDMM. Early discontinuation of dexamethasone did not impact efficacy.","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"22 1","pages":""},"PeriodicalIF":12.8,"publicationDate":"2026-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148459551","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Detailed immunophenotypic and genetic characterization of bone marrow clonal plasma cells and B-cells in early-stage monoclonal gammopathies","authors":"Oihane Pérez-Escurza, P. Martijn Kolijn, Jón Þórir Óskarsson, María González-González, María Jara-Acevedo, Julio del Pozo, Quentin Lécrevisse, Juan Flores-Montero, Luzalba Sanoja-Flores, Silvia Martín, Elín Ruth Reed, Stephen Harding, Sigrún Thorsteinsdottir, Sæmundur Rögnvaldsson, Thorvardur Jon Love, Brian Durie, Anton W. Langerak, Sigurdur Yngvi Kristinsson, Alberto Orfao, , , Albert Orfao","doi":"10.1038/s41408-026-01579-8","DOIUrl":"https://doi.org/10.1038/s41408-026-01579-8","url":null,"abstract":"","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"54 1","pages":""},"PeriodicalIF":12.8,"publicationDate":"2026-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148459550","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}